Matthew Horsfall

Matthew Horsfall


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in JACC
Verified
Journal Article
Closed access
AGAnand N. Ganesan
Anand N. Ganesan
JLJennie Louise
Jennie Louise
MHMatthew Horsfall
Matthew Horsfall
SBShane A. Bilsborough
Shane A. Bilsborough
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
DCDerek P. Chew
Derek P. Chew

1 March 2020 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
CACarolyn M. Astley
Carolyn M. Astley
DCDerek P. Chew
Derek P. Chew
WKWendy Keech
Wendy Keech
SNStephen Nicholls
Stephen Nicholls
JBJohn Beltrame
John Beltrame
RCRobyn A Clark
Robyn A Clark

1 February 2019 in American Heart Journal
Verified
Journal Article
Open access
KLKristina Lambrakis
Kristina Lambrakis
JFJohn K. French
John K. French
ISIan A. Scott
Ian A. Scott
TBTom Briffa
Tom Briffa
DBDavid Brieger
David Brieger
DCDerek P Chew
Derek P Chew
Elevated troponin level findings among patients presenting with suspected acute coronary syndrome (ACS) or another intercurrent illness undeniably identifies patients at increased risk of mortality. Whilst enhancing our capacity to discriminate risk, the use of high-sensitivity troponin assays frequently identifies patients with myocardial injury (i.e. troponin rise without acute signs of myocardial ischemia) or type 2 myocardial infarction (T2MI; oxygen supply-demand imbalance). This leads to the clinically challenging task of distinguishing type 1 myocardial infarction (T1MI; coronary plaque rupture) from myocardial injury and T2MI in the context of concurrent acute illness. Diagnostic discernment in this context is crucial because MI classification has implications for further investigation and care. Early invasive management is of well-established benefit among patients with T1MI. However, the appropriateness of this investigation in the heterogeneous context of T2MI, where there is high competing mortality risk, remains unknown. Although coronary angiography in T2MI is advocated by some, there is insufficient evidence in existing literature to support this opinion as highlighted by current national guidelines. The objective is to evaluate the clinical and economic impact of early invasive management with coronary angiography in T2MI in terms of all-cause mortality and cost effectiveness. This prospective, pragmatic, multicenter, randomized trial among patients with suspected supply demand ischemia leading to troponin elevation (n=1,800; T2MI [1,500], chronic myocardial injury [300]) compares the impact of invasive angiography (or computed tomography angiography as per local preference) within 5 days of randomization versus conservative management (with or without functional testing at clinician discretion) on all-cause mortality by 2 years. Randomized treatment allocation will be stratified by baseline estimated risk of mortality using the Acute Physiology, Age, and Chronic Health Evaluation (APACHE) III risk score. Cost-effectiveness will be evaluated by follow-up on clinical events, quality of life, and resource utilization over 24 months. Ascertaining the most appropriate first-line investigative strategy for these commonly encountered high-risk T2MI patients in a randomized comparative study will be pivotal in informing evidence-based guidelines that lead to better patient and health care outcomes.

1 May 2013 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
DCDerek P. Chew
Derek P. Chew
GJGe Junbo
Ge Junbo
WPWilliam Parsonage
William Parsonage
PKPrafulla Kerkar
Prafulla Kerkar
VSVitaly A. Sulimov
Vitaly A. Sulimov
FIfor the Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) Study Investigators
for the Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) Study Investigators
Background—: Acute coronary syndrome registries report the use of incomplete guideline therapies, especially among the highest risk patients. Whether this treatment gap results from misperceptions of risk by physicians is uncertain. Methods and Results—: The Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) study was a prospective acute coronary syndrome registry in Australia, China, India, and Russia, involving 58 hospitals between May 2009 and February 2011. In-hospital care and events up to 6 months were assessed. At least 2 clinicians involved in patient care estimated the untreated risk and change in risk with each therapy. Physician risk assessment and objective risk measures (eg, Global Registry of Acute Coronary Events [GRACE] score) for death, death/myocardial infarction, and bleeding events were compared using the c statistic and integrated discrimination improvement. In total, 1542 patients and 4230 patient-specific physician estimates were obtained. Of responding clinicians, 81.9% were cardiovascular specialists (years of practice: mean [SD], 11.5 [7.7] years). The median physician-perceived risk of 6-month death was 25% (interquartile range, 14%–35%). The GRACE score was superior to physician estimation (c statistic: GRACE score, 0.812 [95% confidence interval, 0.772–0.851] versus physician, 0.652 [95% confidence interval, 0.596–0.708]; P <0.0001). The GRACE score added to clinician intuition improved discrimination (integrated discrimination improvement, 0.0632 [SE, 0.012]; P <0.0001). Invasive management correlated with physician-estimated risk but not with GRACE risk. Among patients not at high risk by physician estimation, increased risk by GRACE score was associated with higher mortality (3.7% versus 0.8%; P <0.001). Conclusions—: Objective risk assessment provides superior risk discrimination when compared with physician-estimated risk. Whether systematic use of objective risk stratification improves clinical outcomes should be studied in appropriately designed clinical trials.

1 February 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
DCDerek P. Chew
Derek P. Chew
CJCraig Juergens
Craig Juergens
JFJohn French
John French
WPWill Parsonage
Will Parsonage
MHMatthew Horsfall
Matthew Horsfall
Steve QuinnSteve Quinn
Steve Quinn

1 September 2016 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
DCDerek P. Chew
Derek P. Chew
CZChristopher Zeitz
Christopher Zeitz
MWMatthew Worthley
Matthew Worthley
HGHugh Grantham
Hugh Grantham
JBJohn Beltrame
John Beltrame
PAPhilip E.G. Aylward
Philip E.G. Aylward
Background—: High-sensitivity troponin T (hs-TnT) assays promise greater discrimination of evolving myocardial infarction, but the impact of unguided implementation on the effectiveness of care is uncertain. Methods and Results—: We evaluated the impact of hs-TnT reporting on care and outcome among chest pain patients presenting to 5 emergency departments within a multicenter randomized trial. Patients were allocated to hs-TnT reporting (hs-report) or standard reporting (std-report; Roche Elecys). The primary end point was death and new or recurrent acute coronary syndrome by 12 months. A total of 1937 patients without ST-segment elevation were enrolled between July 2011 and March 2013. The median age was 61 (interquartile range, 48–74) years, and 46.3% were women. During the index hospitalization, 1466 patients (75.7%) had maximal troponin <30 ng/L within 24 hours. Randomization to hs-report format did not alter the admission rate (hs-report: 57.7% versus std-report: 58.0%; P =0.069). There was no difference in angiography (hs-report: 11.9% versus std-report: 10.9%; P =0.479). The hs-reporting did not reduce 12-month death or new/recurrent acute coronary syndrome in the overall population (hs-report: 9.7% versus std-report: 7.2% [hazard ratio, 0.83 (0.57–1.22); P =0.362]). However, among those with troponin levels <30 ng/L, a modest reduction in the primary end point was observed (hs-report: 2.6% versus std-report: 4.4%, [hazard ratio, 0.58; 95% confidence interval, 0.34–0.1.00; P =0.050). Conclusions—: High-sensitivity troponin reporting alone is associated with only modest changes in practice. Clinical effectiveness in the adoption of high-sensitivity troponin may require close coupling with protocols that guide interpretation and care. Clinical Trial Registration—: URL: http://www.ANZCTR.org.au . Unique identifier: ACTRN12611000879965.